Ken Griffin
KZR

Ken Griffin’s Kezar Life Sciences KZR Stock Holding History

Ken Griffin’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$441K Buy
+59,403
New +$386K ﹤0.01% 9595
2025
Q4 		– Sell
-18,221
Closed -$71.1K – 13456
2025
Q3 		$71.1K Buy
+18,221
New +$74.7K ﹤0.01% 12031
2025
Q1 		– Sell
-16,870
Closed -$113K – 15093
2024
Q4 		$113K Sell
16,870
-7,676
-31% -$57.2K ﹤0.01% 11283
2024
Q3 		$190K Sell
24,546
-23,773
-49% -$143K ﹤0.01% 10233
2024
Q2 		$290K Sell
48,319
-2,637
-5% -$20K ﹤0.01% 9214
2024
Q1 		$459K Buy
50,956
+14,423
+39% +$131K ﹤0.01% 8583
2023
Q4 		$346K Buy
36,533
+20,308
+125% +$179K ﹤0.01% 8863
2023
Q3 		$193K Sell
16,225
-33,277
-67% -$590K ﹤0.01% 9978
2023
Q2 		$1.21M Sell
49,502
-47,100
-49% -$1.23M ﹤0.01% 6067
2023
Q1 		$3.02M Buy
96,602
+93,689
+3,216% +$5.42M ﹤0.01% 4616
2022
Q4 		$205K Buy
2,913
+1,388
+91% +$103K ﹤0.01% 10092
2022
Q3 		$131K Sell
1,525
-4,485
-75% -$436K ﹤0.01% 10847
2022
Q2 		$497K Sell
6,010
-18,879
-76% -$1.67M ﹤0.01% 8671
2022
Q1 		$4.14M Buy
24,889
+14,489
+139% +$2.08M ﹤0.01% 4542
2021
Q4 		$1.74M Buy
10,400
+6,277
+152% +$709K ﹤0.01% 6571
2021
Q3 		$356K Buy
4,123
+1,180
+40% +$78.1K ﹤0.01% 10683
2021
Q2 		$160K Sell
2,943
-207
-7% -$11.8K ﹤0.01% 12422
2021
Q1 		$188K Buy
3,150
+2,071
+192% +$121K ﹤0.01% 11777
2020
Q4 		$56K Sell
1,079
-336
-24% -$18.7K ﹤0.01% 10528
2020
Q3 		$68K Sell
1,415
-335
-19% -$16K ﹤0.01% 9476
2020
Q2 		$91K Sell
1,750
-90,653
-98% -$4.57M ﹤0.01% 9043
2020
Q1 		$4.03M Buy
92,403
+85,976
+1,338% +$3.5M ﹤0.01% 3009
2019
Q4 		$258K Sell
6,427
-220
-3% -$6.77K ﹤0.01% 7814
2019
Q3 		$218K Buy
6,647
+3,861
+139% +$186K ﹤0.01% 8043
2019
Q2 		$215K Sell
2,786
-1,539
-36% -$239K ﹤0.01% 8092
2019
Q1 		$768K Buy
+4,325
New +$852K ﹤0.01% 6063

Other funds holding KZR

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Ken Griffin's KZR Position: Q1 2026 in Review

Ken Griffin opened a new position in Kezar Life Sciences (KZR) in Q1 2026: 59,403 shares worth $441K. The stake represents ﹤0.01% of the portfolio and ranks #9595 among its holdings. This is a return to the name: Ken Griffin previously reported a position in KZR as recently as Q3 2025.

Ken Griffin first reported a position in KZR in Q1 2019 and has held it in 26 quarters since. The position peaked at $4.14M in Q1 2022. 43 funds tracked by Wall St. Rank hold KZR as of Q1 2026.

  • Ken Griffin held 59,403 shares of Kezar Life Sciences worth $441K as of Q1 2026.
  • Kezar Life Sciences was a new Ken Griffin position in Q1 2026.
  • Kezar Life Sciences made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #9595 holding.
  • Ken Griffin first reported a position in Kezar Life Sciences in Q1 2019 and has held it in 26 quarters since.
  • Ken Griffin's Kezar Life Sciences position peaked at $4.14M in Q1 2022.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.